These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36572760)

  • 1. Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation.
    Zhu J; Chen J
    Mol Biol Rep; 2023 Mar; 50(3):2909-2917. PubMed ID: 36572760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation.
    Maurer K; Soiffer RJ
    Expert Rev Hematol; 2023; 16(12):943-962. PubMed ID: 37906445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tang Y; Zhou Z; Yan H; You Y
    Front Immunol; 2022; 13():810284. PubMed ID: 35185899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virotherapy in hematopoietic stem cell transplantation.
    Kazemi MH; Kuhestani Dehaghi B; Roshandel E; Parkhideh S; Mehdizadeh M; Salimi M; Hajifathali A; Hamidpour M
    Hum Immunol; 2021 Sep; 82(9):640-648. PubMed ID: 34119352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.
    Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA
    Front Immunol; 2019; 10():295. PubMed ID: 30891031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised trials of Graft versus Host Disease prophylaxis in haemopoietic stem cell transplantation.
    Potter V; Moore J
    Rev Recent Clin Trials; 2008 May; 3(2):130-8. PubMed ID: 18474024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
    Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.
    Zaghi E; Calvi M; Di Vito C; Mavilio D
    Front Immunol; 2019; 10():2794. PubMed ID: 31849972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
    Mushtaq MU; Shahzad M; Shah AY; Chaudhary SG; Zafar MU; Anwar I; Neupane K; Khalid A; Ahmed N; Bansal R; Balusu R; Singh AK; Abhyankar SH; Callander NS; Hematti P; McGuirk JP
    Front Immunol; 2022; 13():1005031. PubMed ID: 36263054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute graft versus host disease in hematopoietic stem cell alotransplant recipients.
    Krstevska S; Genadieva-Stavric S; Pivkova A; Stojanovski Z; Georgievski B; Balkanov T
    Med Arh; 2011; 65(5):260-4. PubMed ID: 22073847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
    Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation.
    Köhler N; Ruess DA; Kesselring R; Zeiser R
    Front Immunol; 2021; 12():634435. PubMed ID: 33746972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
    Chang YJ; Huang XJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies.
    Saliba RM; Srour SA; Greenbaum U; Ma Q; Carmazzi Y; Moller M; Wood J; Ciurea SO; Kongtim P; Rondon G; Li D; Saengboon S; Alousi AM; Rezvani K; Shpall EJ; Cao K; Champlin RE; Zou J
    Front Immunol; 2022; 13():904718. PubMed ID: 35874659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy.
    Dertschnig S; Gergely P; Finke J; Schanz U; Holler E; Holtick U; Socié G; Medinger M; Passweg J; Teshima T; Stylianou C; Oehen S; Heim D; Bucher C
    Transplant Cell Ther; 2023 Jan; 29(1):41.e1-41.e9. PubMed ID: 36343893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.